South Korea-based biopharmaceutical company Celltrion Inc (KRX:068270) on Monday reported post-hoc analyses from the LIBERTY-CD and LIBERTY-UC Phase 3 studies showing that subcutaneous infliximab (Remsima SC) restored and maintained clinical response in most Crohn's disease and ulcerative colitis patients following treatment interruption after intravenous induction.

The findings, based on patients experiencing drug holidays of at least 16 weeks, will be presented at the 21st Congress of the European Crohn's and Colitis Organisation in Stockholm, Sweden.

Among 51 Crohn's disease and 77 ulcerative colitis patients initiating subcutaneous infliximab 240 mg, clinical response emerged by approximately eight weeks and persisted through Week 102 with stable serum drug levels and no new safety signals. At study end, faecal calprotectin remission was achieved in 61.1% of Crohn's disease and 65.2% of ulcerative colitis patients, while endoscopic response or improvement reached 64.0% and 68.8%, respectively; treatment persistence was 72.3% and 61.9%. The analysis supports subcutaneous infliximab as an effective and safe option to recapture and maintain disease control after planned or unplanned treatment interruption.